StockNews.AI
INSP
StockNews.AI
183 days

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Inspire Medical Systems, Inc. (NYSE: INSP) and Encourages Long-Term Inspire Investors to Contact the Firm

1. Inspire Medical faces securities fraud complaints from investors. 2. The fraud claims relate to misleading statements about their Acceleration Program. 3. Inspire reported a disappointing earnings miss, leading to a significant share price drop. 4. The investigation aims to determine potential fiduciary breaches by board members. 5. Investors are encouraged to contact legal counsel regarding their rights.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The filing of a securities fraud complaint suggests significant credibility issues, which often lead to declines in stock value. Similar past incidents for other companies resulted in prolonged stock price recovery periods.

How important is it?

The legal issues and the negative impact on earnings directly affect shareholder interests and company valuation, making this highly relevant for INSP's stock.

Why Short Term?

The immediate fallout from the earnings miss and fraud allegations typically influences stock price rapidly. Over time, if issues are resolved, the price may stabilize.

Related Companies

SPYAMGNABT
PHILADELPHIA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire Medical”) on behalf of the company’s long-term shareholders. Click here for additional information: https://kaskelalaw.com/cases/inspire-medical-systems/ Recently a securities fraud complaint was filed against Inspire Medical on behalf of certain investors who purchased shares of the company’s stock between May 3, 2023 and November 7, 2023. According to the complaint, during that time period Inspire Medical and certain of the company’s senior executives made a series of materially false and/or misleading statements about the company’s “Acceleration Program,” which was reportedly designed to facilitate customers’ receiving prior authorizations from doctors for Inspire Medical’s sleep apnea products (“Inspire therapy”) by acting as a liaison between patients and their doctors. As detailed in the complaint, on November 7, 2023, Inspire Medical announced disappointing earnings results for the third quarter of 2023 – its first reported revenue miss since becoming a public company in 2018. Therein, the company disclosed that it had started to “track” problems with the Acceleration Program in the second quarter of 2023, including a decrease in the number of prior authorization submissions for Inspire therapy, and “recogniz[ed] this trend early in the third quarter” (i.e., as early as July 1, 2023). Following this news, shares of Inspire Medical’s stock fell $31.79 per share, or nearly 20% in value, from a closing price of $161.74 per share on November 7, 2023 to a closing price of $129.65 per share on November 8, 2023. The investigation seeks to determine whether the members of Inspire Medical’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct. Inspire Medical shareholders who purchased or acquired their currently held INSP shares prior to May 3, 2023 are encouraged to contact Kaskela Law LLC shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750 for additional information about this investigation and their legal rights and options. Alternatively, investors may submit their information to the firm by clicking on the following link (or if necessary, by copying and pasting the link into your browser): https://kaskelalaw.com/cases/inspire-medical-systems/ Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. CONTACT: KASKELA LAW LLC D. Seamus Kaskela, Esq.(skaskela@kaskelalaw.com)Adrienne Bell, Esq.(abell@kaskelalaw.com)18 Campus Blvd., Suite 100Newtown Square, PA 19073(888) 715 – 1740(484) 229 – 0750www.kaskelalaw.com This notice may constitute attorney advertising in certain jurisdictions.  

Related News